Neladalkib在治疗先进的ALK阳性固态肿瘤(包括脑转移)方面显示出令人乐观的结果,反应率达到44%,而且安全性良好。 Neladalkib showed promising results in treating advanced ALK-positive solid tumors, including brain metastases, with a 44% response rate and good safety.

Nuvalent报告其ALKOVE-1试验的初步结果显示,调查的ALK抑制剂Neladalkib在34名患有超过肺癌的高级ALK阳性固态肿瘤(包括罕见癌症和脑转移)的病人中实现了44%的客观反应率。 Nuvalent reported preliminary results from its ALKOVE-1 trial showing neladalkib, an investigational ALK inhibitor, achieved a 44% objective response rate in 34 patients with advanced ALK-positive solid tumors beyond lung cancer, including rare cancers and those with brain metastases. 大多数病人每天得到150毫克剂量的剂量,80%的应答者保持反应,没有进展。 Most patients received the 150 mg daily dose, with 80% of responders maintaining response without progression. 该药物显示了有利的安全性特征和跨越血脑屏障的潜力。 The drug showed a favorable safety profile and potential to cross the blood-brain barrier. 第二阶段的入院工作继续进行,预计到2025年底,接受TKTI前科治疗的NSCLC的TKI患者的上线结果将到2025年底,目前正在对治疗后科治疗的NSCL病人进行第3阶段的试验。 Enrollment continues in the Phase 2 portion, with topline results for TKI-pre-treated NSCLC expected by year-end 2025 and a Phase 3 trial ongoing for treatment-naïve NSCLC patients.